Molecular Hematopathology -MSH- 2021

Occurs weekly every Monday, Tuesday, Wednesday, and Thursday starting on 1/4/2021 at 5:00 PM
Monday, January 4, 2021, 5:00 PM - 6:00 PM, Online, New York, NY


Weekly conferences on Leukemia, Myeloma, Lymphoma presenting interesting, complex, diagnostic or therapeutically challenging and educational cases. Presentation formats include clinical histories, radiology, nuclear medicine, pathology, molecular, cytogenomics, and therapy management discussions, with literature reviews. Audience includes medical students, residents, fellows, research scientists, nurses, physician assistants, and faculty to keep updated on latest classifications, and developments in the fields of Hematopathology, Hematology, Molecular, Cell-Based Medicine, Immunology, and ImmunoOncology.

1. Describe recent WHO updates for myeloid and lymphoid neoplasms
2. Identify barriers and an action plan to increase appropriate molecular mutation testing for hematopoietic neoplasms, in particular, myeloid and lymphoid neoplasms
3. To better explain to patients and how to appropriately manage patients with myeloid and lymphoid neoplasms
4. To describe novel gene networks; to have an action plan to use available in house technology and testing for hematopoietic neoplasms, in particular plasma cell neoplasms, and how to appropriately manage these patients

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Date	Empty Column	Title
		No activities are currently published for this month.
No upcoming dates have been setup.